These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24023668)

  • 1. Inhibition of oxidative stress-elicited AKT activation facilitates PPARγ agonist-mediated inhibition of stem cell character and tumor growth of liver cancer cells.
    Liu L; Yang Z; Xu Y; Li J; Xu D; Zhang L; Sun J; Xia S; Zou F; Liu Y
    PLoS One; 2013; 8(8):e73038. PubMed ID: 24023668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
    Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
    Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice.
    Shen B; Chu ES; Zhao G; Man K; Wu CW; Cheng JT; Li G; Nie Y; Lo CM; Teoh N; Farrell GC; Sung JJ; Yu J
    Br J Cancer; 2012 Apr; 106(9):1486-94. PubMed ID: 22472882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPARgamma agonists inhibit growth and expansion of CD133+ brain tumour stem cells.
    Chearwae W; Bright JJ
    Br J Cancer; 2008 Dec; 99(12):2044-53. PubMed ID: 19018263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined effect of honokiol and rosiglitazone on cell growth inhibition through enhanced G0/G1 phase arrest in hepatoma cells.
    Chen HC; Hsu HT; Weng JW; Chang YF; Hsia CY; Lee HC; Chi CW
    J Chin Med Assoc; 2016 Aug; 79(8):415-21. PubMed ID: 27094504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A PPARgamma agonist inhibits aldosterone-induced mesangial cell proliferation by blocking ROS-dependent EGFR intracellular signaling.
    Yuan Y; Zhang A; Huang S; Ding G; Chen R
    Am J Physiol Renal Physiol; 2011 Feb; 300(2):F393-402. PubMed ID: 21123490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
    Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
    Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 15-Deoxy-Delta12,14-prostaglandin J(2) induces death receptor 5 expression through mRNA stabilization independently of PPARgamma and potentiates TRAIL-induced apoptosis.
    Nakata S; Yoshida T; Shiraishi T; Horinaka M; Kouhara J; Wakada M; Sakai T
    Mol Cancer Ther; 2006 Jul; 5(7):1827-35. PubMed ID: 16891469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
    Grabinski N; Ewald F; Hofmann BT; Staufer K; Schumacher U; Nashan B; Jücker M
    Mol Cancer; 2012 Nov; 11():85. PubMed ID: 23167739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combinatory effects of PPAR-γ agonist and survivin inhibition on the cancer stem-like phenotype and cell proliferation in bladder cancer cells.
    Wang Y; Tan H; Xu D; Ma A; Zhang L; Sun J; Yang Z; Liu Y; Shi G
    Int J Mol Med; 2014 Jul; 34(1):262-8. PubMed ID: 24820432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 15d-PGJ2 induces apoptosis by reactive oxygen species-mediated inactivation of Akt in leukemia and colorectal cancer cells and shows in vivo antitumor activity.
    Shin SW; Seo CY; Han H; Han JY; Jeong JS; Kwak JY; Park JI
    Clin Cancer Res; 2009 Sep; 15(17):5414-25. PubMed ID: 19690198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations.
    Yang Z; Zhang L; Ma A; Liu L; Li J; Gu J; Liu Y
    PLoS One; 2011; 6(12):e28405. PubMed ID: 22145042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disulfiram eradicates tumor-initiating hepatocellular carcinoma cells in ROS-p38 MAPK pathway-dependent and -independent manners.
    Chiba T; Suzuki E; Yuki K; Zen Y; Oshima M; Miyagi S; Saraya A; Koide S; Motoyama T; Ogasawara S; Ooka Y; Tawada A; Nakatsura T; Hayashi T; Yamashita T; Kaneko S; Miyazaki M; Iwama A; Yokosuka O
    PLoS One; 2014; 9(1):e84807. PubMed ID: 24454751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling.
    Tang KH; Ma S; Lee TK; Chan YP; Kwan PS; Tong CM; Ng IO; Man K; To KF; Lai PB; Lo CM; Guan XY; Chan KW
    Hepatology; 2012 Mar; 55(3):807-20. PubMed ID: 21994122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPARgamma activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404.
    Zhang W; Wu N; Li Z; Wang L; Jin J; Zha XL
    Cancer Biol Ther; 2006 Aug; 5(8):1008-14. PubMed ID: 16775433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The peroxisome proliferator-activated receptor gamma ligands, pioglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells.
    Shim J; Kim BH; Kim YI; Kim KY; Hwangbo Y; Jang JY; Dong SH; Kim HJ; Chang YW; Chang R
    Int J Oncol; 2010 Jan; 36(1):223-31. PubMed ID: 19956851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nox2-derived ROS in PPARγ signaling and cell-cycle progression of lung alveolar epithelial cells.
    Tickner J; Fan LM; Du J; Meijles D; Li JM
    Free Radic Biol Med; 2011 Aug; 51(3):763-72. PubMed ID: 21664456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of peroxisome proliferator-activated receptor-γ (PPARγ) inhibits hepatoma cell growth via downregulation of SEPT2 expression.
    Cao LQ; Shao ZL; Liang HH; Zhang DW; Yang XW; Jiang XF; Xue P
    Cancer Lett; 2015 Apr; 359(1):127-35. PubMed ID: 25592041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hispidulin inhibits hepatocellular carcinoma growth and metastasis through AMPK and ERK signaling mediated activation of PPARγ.
    Han M; Gao H; Ju P; Gao MQ; Yuan YP; Chen XH; Liu KL; Han YT; Han ZW
    Biomed Pharmacother; 2018 Jul; 103():272-283. PubMed ID: 29656183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.
    Ma S; Lee TK; Zheng BJ; Chan KW; Guan XY
    Oncogene; 2008 Mar; 27(12):1749-58. PubMed ID: 17891174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.